{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T09:09:41Z","timestamp":1789549781634,"version":"build-2803163510"},"reference-count":82,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T00:00:00Z","timestamp":1789516800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T00:00:00Z","timestamp":1789516800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Calcif Tissue Int"],"DOI":"10.1007\/s00223-026-01603-w","type":"journal-article","created":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T08:58:29Z","timestamp":1789549109000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The Liver-Bone Axis in Steatotic Liver Disease"],"prefix":"10.1007","volume":"117","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-1617-8426","authenticated-orcid":false,"given":"Krzysztof","family":"\u0141upina","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-3726-803X","authenticated-orcid":false,"given":"Adrian","family":"Nowak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-7609-859X","authenticated-orcid":false,"given":"Anna","family":"Romac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-6214-8564","authenticated-orcid":false,"given":"Paulina","family":"Jaskulska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-8228-7015","authenticated-orcid":false,"given":"Weronika","family":"St\u0119pie\u0144","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-5384-7309","authenticated-orcid":false,"given":"Aleksandra","family":"Kalisz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-3838-9503","authenticated-orcid":false,"given":"Kamil","family":"Jo\u0144czyk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-7977-9797","authenticated-orcid":false,"given":"Jakub","family":"Janczura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,16]]},"reference":[{"key":"1603_CR1","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1111\/apt.17846","volume":"59","author":"R Loomba","year":"2024","unstructured":"Loomba R, Wong VW (2024) Implications of the new nomenclature of steatotic liver disease and definition of metabolic dysfunction-associated steatotic liver disease. Aliment Pharmacol Ther 59:150\u2013156. https:\/\/doi.org\/10.1111\/apt.17846","journal-title":"Aliment Pharmacol Ther"},{"key":"1603_CR2","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1097\/HEP.0000000000000520","volume":"78","author":"ME Rinella","year":"2023","unstructured":"Rinella ME, Lazarus JV, Ratziu V et al (2023) A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Hepatology 78:1966\u20131986. https:\/\/doi.org\/10.1097\/HEP.0000000000000520","journal-title":"Hepatology"},{"key":"1603_CR3","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2025.1543003","volume":"16","author":"J Zhang","year":"2025","unstructured":"Zhang J, Sun Z, Xu L et al (2025) Unraveling the link between metabolic dysfunction-associated steatotic liver disease and osteoporosis: a bridging function of gut microbiota. Front Endocrinol 16:1543003. https:\/\/doi.org\/10.3389\/fendo.2025.1543003","journal-title":"Front Endocrinol"},{"key":"1603_CR4","doi-asserted-by":"publisher","first-page":"61","DOI":"10.4082\/kjfm.25.0027","volume":"46","author":"D Lorek","year":"2025","unstructured":"Lorek D, \u0141upina K, Bisaga W et al (2025) The socioeconomic and environmental determinants of metabolic dysfunction-associated steatotic liver disease: understanding inequalities in prevalence and outcomes. Korean J Fam Med 46:61\u201369. https:\/\/doi.org\/10.4082\/kjfm.25.0027","journal-title":"Korean J Fam Med"},{"key":"1603_CR5","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1016\/j.jhep.2024.04.031","volume":"81","author":"European Association for the Study of the Liver (EASL)","year":"2024","unstructured":"European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), European Association for the Study of Obesity (EASO), European Association for the Study of the Liver (EASL) (2024) EASL-EASD-EASO Clinical practice guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). J Hepatol 81:492\u2013542. https:\/\/doi.org\/10.1016\/j.jhep.2024.04.031","journal-title":"J Hepatol"},{"key":"1603_CR6","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-025-02674-9","volume":"42","author":"P Starnawski","year":"2025","unstructured":"Starnawski P, Nowak K, Augustyn Z et al (2025) Role of hepatotropic viruses in promoting hepatocellular carcinoma\u2014current knowledge and recent advances. Med Oncol 42:111. https:\/\/doi.org\/10.1007\/s12032-025-02674-9","journal-title":"Med Oncol"},{"key":"1603_CR7","doi-asserted-by":"publisher","first-page":"219","DOI":"10.5114\/ceh.2025.154220","volume":"11","author":"J Janczura","year":"2025","unstructured":"Janczura J, Mangia A, Dobrowolska K et al (2025) Steatotic liver disease and chronic viral hepatitis. Clin Exp Hepatol 11:219\u2013227. https:\/\/doi.org\/10.5114\/ceh.2025.154220","journal-title":"Clin Exp Hepatol"},{"key":"1603_CR8","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1016\/j.clnu.2024.04.034","volume":"43","author":"S Yokoyama","year":"2024","unstructured":"Yokoyama S, Honda T, Ishizu Y et al (2024) Risk factors for decreased bone mineral density in patients with metabolic dysfunction-associated steatotic liver disease: a cross-sectional study at a health examination center. Clin Nutr 43:1425\u20131432. https:\/\/doi.org\/10.1016\/j.clnu.2024.04.034","journal-title":"Clin Nutr"},{"key":"1603_CR9","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25179193","volume":"25","author":"F Monti","year":"2024","unstructured":"Monti F, Perazza F, Leoni L et al (2024) RANK\u2013RANKL\u2013OPG axis in MASLD: current evidence linking bone and liver diseases and future perspectives. Int J Mol Sci 25:9193. https:\/\/doi.org\/10.3390\/ijms25179193","journal-title":"Int J Mol Sci"},{"key":"1603_CR10","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.1063815","volume":"13","author":"Y Zhang","year":"2022","unstructured":"Zhang Y, Liang J, Liu P et al (2022) The RANK\/RANKL\/OPG system and tumor bone metastasis: potential mechanisms and therapeutic strategies. Front Endocrinol (Lausanne) 13:1063815. https:\/\/doi.org\/10.3389\/fendo.2022.1063815","journal-title":"Front Endocrinol (Lausanne)"},{"key":"1603_CR11","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/j.metabol.2015.12.005","volume":"65","author":"Y Niu","year":"2016","unstructured":"Niu Y, Zhang W, Yang Z et al (2016) Plasma osteoprotegerin levels are inversely associated with nonalcoholic fatty liver disease in patients with type 2 diabetes: a case-control study in China. Metabolism 65:475\u2013481. https:\/\/doi.org\/10.1016\/j.metabol.2015.12.005","journal-title":"Metabolism"},{"key":"1603_CR12","doi-asserted-by":"publisher","DOI":"10.1007\/s11427-025-3207-5","author":"S Han","year":"2026","unstructured":"Han S, Wei Y, Yu G et al (2026) The liver-bone axis: an emerging player in disease pathogenesis and therapeutic intervention. Sci China Life Sci. https:\/\/doi.org\/10.1007\/s11427-025-3207-5","journal-title":"Sci China Life Sci"},{"key":"1603_CR13","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20102555","volume":"20","author":"S Ehnert","year":"2019","unstructured":"Ehnert S, Aspera-Werz RH, Ruo\u00df M et al (2019) Hepatic osteodystrophy-molecular mechanisms proposed to favor its development. Int J Mol Sci 20:2555. https:\/\/doi.org\/10.3390\/ijms20102555","journal-title":"Int J Mol Sci"},{"key":"1603_CR14","doi-asserted-by":"publisher","first-page":"108","DOI":"10.7570\/jomes24004","volume":"33","author":"S Khanmohammadi","year":"2024","unstructured":"Khanmohammadi S, Kuchay MS (2024) Effects of metabolic dysfunction-associated steatotic liver disease on bone density and fragility fractures: associations and mechanisms. J Obes Metab Syndr 33:108\u2013120. https:\/\/doi.org\/10.7570\/jomes24004","journal-title":"J Obes Metab Syndr"},{"key":"1603_CR15","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/s13679-025-00643-x","volume":"14","author":"I Filimidou","year":"2025","unstructured":"Filimidou I, Orfanidou M, Goulas A et al (2025) Circulating fibroblast growth factor-21 in patients with nonalcoholic fatty liver disease: a systematic review and meta-analysis. Curr Obes Rep 14:51. https:\/\/doi.org\/10.1007\/s13679-025-00643-x","journal-title":"Curr Obes Rep"},{"key":"1603_CR16","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1002\/ueg2.12534","volume":"12","author":"R Gallego-Dur\u00e1n","year":"2024","unstructured":"Gallego-Dur\u00e1n R, Ampuero J, Maya-Miles D et al (2024) Fibroblast growth factor 21 is a hepatokine involved in MASLD progression. United Eur Gastroenterol J 12:1056\u20131068. https:\/\/doi.org\/10.1002\/ueg2.12534","journal-title":"United Eur Gastroenterol J"},{"key":"1603_CR17","doi-asserted-by":"publisher","first-page":"3143","DOI":"10.1073\/pnas.1200797109","volume":"109","author":"W Wei","year":"2012","unstructured":"Wei W, Dutchak PA, Wang X et al (2012) Fibroblast growth factor 21 promotes bone loss by potentiating the effects of peroxisome proliferator-activated receptor \u03b3. Proc Natl Acad Sci U S A 109:3143\u20133148. https:\/\/doi.org\/10.1073\/pnas.1200797109","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1603_CR18","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1016\/j.cmet.2015.09.010","volume":"22","author":"X Wang","year":"2015","unstructured":"Wang X, Wei W, Krzeszinski JY et al (2015) A liver-bone endocrine relay by IGFBP1 promotes osteoclastogenesis and mediates FGF21-induced bone resorption. Cell Metab 22:811\u2013824. https:\/\/doi.org\/10.1016\/j.cmet.2015.09.010","journal-title":"Cell Metab"},{"key":"1603_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2020.173291","volume":"882","author":"N Tang","year":"2020","unstructured":"Tang N, Rao S, Ying Y, Huang Y (2020) New insights into BMP9 signaling in organ fibrosis. Eur J Pharmacol 882:173291. https:\/\/doi.org\/10.1016\/j.ejphar.2020.173291","journal-title":"Eur J Pharmacol"},{"key":"1603_CR20","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1038\/s41374-018-0087-7","volume":"99","author":"J Cui","year":"2019","unstructured":"Cui J, Zhang W, Huang E et al (2019) BMP9-induced osteoblastic differentiation requires functional Notch signaling in mesenchymal stem cells. Lab Invest 99:58\u201371. https:\/\/doi.org\/10.1038\/s41374-018-0087-7","journal-title":"Lab Invest"},{"key":"1603_CR21","doi-asserted-by":"publisher","unstructured":"Ma J, Wang A, Zhang H, et al (2022) Iron overload induced osteocytes apoptosis and led to bone loss in Hepcidin\u2212\/\u2212 mice through increasing sclerostin and RANKL\/OPG. Bone 164:. https:\/\/doi.org\/10.1016\/j.bone.2022.116511","DOI":"10.1016\/j.bone.2022.116511"},{"key":"1603_CR22","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.cmet.2022.02.002","volume":"34","author":"M Zaidi","year":"2022","unstructured":"Zaidi M, Yuen T, Iqbal J (2022) Reverse cholesterol transport and hepatic osteodystrophy. Cell Metab 34:347\u2013349. https:\/\/doi.org\/10.1016\/j.cmet.2022.02.002","journal-title":"Cell Metab"},{"key":"1603_CR23","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25094901","volume":"25","author":"I Aggeletopoulou","year":"2024","unstructured":"Aggeletopoulou I, Tsounis EP, Triantos C (2024) Vitamin D and metabolic dysfunction-associated steatotic liver disease (MASLD): novel mechanistic insights. Int J Mol Sci 25:4901. https:\/\/doi.org\/10.3390\/ijms25094901","journal-title":"Int J Mol Sci"},{"key":"1603_CR24","doi-asserted-by":"publisher","first-page":"2624","DOI":"10.1007\/s10620-009-1069-9","volume":"55","author":"J Arteh","year":"2010","unstructured":"Arteh J, Narra S, Nair S (2010) Prevalence of vitamin D deficiency in chronic liver disease. Dig Dis Sci 55:2624\u20132628. https:\/\/doi.org\/10.1007\/s10620-009-1069-9","journal-title":"Dig Dis Sci"},{"key":"1603_CR25","doi-asserted-by":"publisher","first-page":"135","DOI":"10.14218\/JCTH.2017.00055","volume":"6","author":"Z Jamil","year":"2018","unstructured":"Jamil Z, Arif S, Khan A et al (2018) Vitamin D deficiency and its relationship with Child-Pugh class in patients with chronic liver disease. J Clin Transl Hepatol 6:135\u2013140. https:\/\/doi.org\/10.14218\/JCTH.2017.00055","journal-title":"J Clin Transl Hepatol"},{"key":"1603_CR26","doi-asserted-by":"publisher","first-page":"2511","DOI":"10.1007\/s00394-018-1803-1","volume":"58","author":"S Giuliani","year":"2019","unstructured":"Giuliani S, Barbieri V, Di Pierro AM et al (2019) LC-MS\/MS based 25(OH)D status in a large Southern European outpatient cohort: gender- and age-specific differences. Eur J Nutr 58:2511\u20132520. https:\/\/doi.org\/10.1007\/s00394-018-1803-1","journal-title":"Eur J Nutr"},{"key":"1603_CR27","doi-asserted-by":"publisher","first-page":"2180","DOI":"10.1002\/hep.25930","volume":"56","author":"I Barchetta","year":"2012","unstructured":"Barchetta I, Carotti S, Labbadia G et al (2012) Liver vitamin D receptor, CYP2R1, and CYP27A1 expression: relationship with liver histology and vitamin D3 levels in patients with nonalcoholic steatohepatitis or hepatitis C virus. Hepatology 56:2180\u20132187. https:\/\/doi.org\/10.1002\/hep.25930","journal-title":"Hepatology"},{"key":"1603_CR28","doi-asserted-by":"publisher","DOI":"10.1002\/dmrr.3628","author":"S Ciardullo","year":"2023","unstructured":"Ciardullo S, Muraca E, Cannistraci R et al (2023) Low 25(OH) vitamin D levels are associated with increased prevalence of nonalcoholic fatty liver disease and significant liver fibrosis. Diabetes Metab Res Rev. https:\/\/doi.org\/10.1002\/dmrr.3628","journal-title":"Diabetes Metab Res Rev"},{"key":"1603_CR29","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-31256-w","volume":"13","author":"AM Hassan","year":"2023","unstructured":"Hassan AM, Haridy MA, Shoaeir MZ et al (2023) Non-alcoholic fatty liver disease is associated with decreased bone mineral density in upper Egyptian patients. Sci Rep 13:4353. https:\/\/doi.org\/10.1038\/s41598-023-31256-w","journal-title":"Sci Rep"},{"key":"1603_CR30","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1007\/s00223-022-00955-3","volume":"112","author":"N Alonso","year":"2023","unstructured":"Alonso N, Meinitzer A, Fritz-Petrin E et al (2023) Role of vitamin K in bone and muscle metabolism. Calcif Tissue Int 112:178\u2013196. https:\/\/doi.org\/10.1007\/s00223-022-00955-3","journal-title":"Calcif Tissue Int"},{"key":"1603_CR31","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1111\/j.1572-0241.2002.05618","volume":"97","author":"S Shiomi","year":"2002","unstructured":"Shiomi S, Nishiguchi S, Kubo S et al (2002) Vitamin K2 (menatetrenone) for bone loss in patients with cirrhosis of the liver. Am J Gastroenterol 97:978\u2013981. https:\/\/doi.org\/10.1111\/j.1572-0241.2002.05618","journal-title":"Am J Gastroenterol"},{"key":"1603_CR32","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1080\/10408363.2024.2323132","volume":"61","author":"M Herrmann","year":"2024","unstructured":"Herrmann M, Rodriguez-Blanco G, Balasso M et al (2024) The role of bile acid metabolism in bone and muscle: from analytics to mechanisms. Crit Rev Clin Lab Sci 61:510\u2013528. https:\/\/doi.org\/10.1080\/10408363.2024.2323132","journal-title":"Crit Rev Clin Lab Sci"},{"key":"1603_CR33","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1159\/000369352","volume":"91","author":"DH Sinn","year":"2015","unstructured":"Sinn DH, Gwak GY, Rhee SY et al (2015) Association between serum osteocalcin levels and non-alcoholic fatty liver disease in women. Digestion 91:150\u2013157. https:\/\/doi.org\/10.1159\/000369352","journal-title":"Digestion"},{"key":"1603_CR34","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1016\/j.cell.2007.05.047","volume":"130","author":"NK Lee","year":"2007","unstructured":"Lee NK, Sowa H, Hinoi E et al (2007) Endocrine regulation of energy metabolism by the skeleton. Cell 130:456\u2013469. https:\/\/doi.org\/10.1016\/j.cell.2007.05.047","journal-title":"Cell"},{"key":"1603_CR35","doi-asserted-by":"publisher","first-page":"4135","DOI":"10.2147\/DMSO.S328829","volume":"14","author":"W Cao","year":"2021","unstructured":"Cao W, Xu Y, Shen Y et al (2021) Serum fibroblast growth factor 23 level and liver fat content in MAFLD: a community-based cohort. Diabetes Metab Syndr Obes 14:4135\u20134143. https:\/\/doi.org\/10.2147\/DMSO.S328829","journal-title":"Diabetes Metab Syndr Obes"},{"key":"1603_CR36","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.114","author":"Z Li","year":"2023","unstructured":"Li Z, Wen X, Li N et al (2023) The roles of hepatokine and osteokine in liver-bone crosstalk: advance in basic and clinical aspects. Front Endocrinol (Lausanne). https:\/\/doi.org\/10.3389\/fendo.2023.114","journal-title":"Front Endocrinol (Lausanne)"},{"key":"1603_CR37","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1007\/s11154-015-9311-6","volume":"16","author":"M Sharifi","year":"2015","unstructured":"Sharifi M, Ereifej L, Lewiecki EM (2015) Sclerostin and skeletal health. Rev Endocr Metab Disord 16:149\u2013156. https:\/\/doi.org\/10.1007\/s11154-015-9311-6","journal-title":"Rev Endocr Metab Disord"},{"key":"1603_CR38","doi-asserted-by":"publisher","DOI":"10.3390\/nu14132574","author":"M Gonz\u00e1lez","year":"2022","unstructured":"Gonz\u00e1lez M, Rodr\u00edguez F, Gonz\u00e1lez A et al (2022) Sclerostin in excessive drinkers: relationships with liver function and body composition. Nutrients. https:\/\/doi.org\/10.3390\/nu14132574","journal-title":"Nutrients"},{"key":"1603_CR39","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-72172-9","author":"J Chen","year":"2020","unstructured":"Chen J, Argemi J, Odena G et al (2020) Hepatic lipocalin 2 promotes liver fibrosis and portal hypertension. Sci Rep. https:\/\/doi.org\/10.1038\/s41598-020-72172-9","journal-title":"Sci Rep"},{"key":"1603_CR40","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.1016\/j.jhep.2023.08.030","volume":"79","author":"AL Hutchison","year":"2023","unstructured":"Hutchison AL, Tavaglione F, Romeo S, Charlton M (2023) Endocrine aspects of metabolic dysfunction-associated steatotic liver disease (MASLD): beyond insulin resistance. J Hepatol 79:1524\u20131541. https:\/\/doi.org\/10.1016\/j.jhep.2023.08.030","journal-title":"J Hepatol"},{"key":"1603_CR41","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1007\/s00125-024-06172-x","volume":"67","author":"A Sheu","year":"2024","unstructured":"Sheu A, White CP, Center JR (2024) Bone metabolism in diabetes: a clinician\u2019s guide to understanding the bone-glucose interplay. Diabetologia 67:1493\u20131506. https:\/\/doi.org\/10.1007\/s00125-024-06172-x","journal-title":"Diabetologia"},{"key":"1603_CR42","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1278505","volume":"14","author":"W Zhang","year":"2023","unstructured":"Zhang W, Li Y, Li S et al (2023) Associations of metabolic dysfunction-associated fatty liver disease and hepatic fibrosis with bone mineral density and risk of osteopenia\/osteoporosis in T2DM patients. Front Endocrinol (Lausanne) 14:1278505. https:\/\/doi.org\/10.3389\/fendo.2023.1278505","journal-title":"Front Endocrinol (Lausanne)"},{"key":"1603_CR43","doi-asserted-by":"publisher","first-page":"8583","DOI":"10.18632\/aging.103168","volume":"12","author":"J He","year":"2020","unstructured":"He J, Xu S, Zhang B et al (2020) Gut microbiota and metabolite alterations associated with reduced bone mineral density or bone metabolic indexes in postmenopausal osteoporosis. Aging (Albany NY) 12:8583\u20138604. https:\/\/doi.org\/10.18632\/aging.103168","journal-title":"Aging (Albany NY)"},{"key":"1603_CR44","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1002\/jcsm.12754","volume":"12","author":"HS Chun","year":"2021","unstructured":"Chun HS, Kim MN, Lee JS et al (2021) Risk stratification using sarcopenia status among subjects with metabolic dysfunction-associated fatty liver disease. J Cachexia Sarcopenia Muscle 12:1168\u20131178. https:\/\/doi.org\/10.1002\/jcsm.12754","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"1603_CR45","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.599339","volume":"12","author":"HJ Lee","year":"2021","unstructured":"Lee HJ, Lee DC, Kim CO (2021) Association between 10-year fracture probability and nonalcoholic fatty liver disease with or without sarcopenia in Korean men: a nationwide population-based cross-sectional study. Front Endocrinol 12:599339. https:\/\/doi.org\/10.3389\/fendo.2021.599339","journal-title":"Front Endocrinol"},{"key":"1603_CR46","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1016\/j.injury.2020.02.072","volume":"51","author":"H Chen","year":"2020","unstructured":"Chen H, Ma J, Liu A et al (2020) The association between sarcopenia and fracture in middle-aged and elderly people: a systematic review and meta-analysis of cohort studies. Injury 51:804\u2013811. https:\/\/doi.org\/10.1016\/j.injury.2020.02.072","journal-title":"Injury"},{"key":"1603_CR47","doi-asserted-by":"publisher","first-page":"2173","DOI":"10.1007\/s00198-021-05963-x","volume":"32","author":"Z Teng","year":"2021","unstructured":"Teng Z, Zhu Y, Teng Y et al (2021) The analysis of osteosarcopenia as a risk factor for fractures, mortality, and falls. Osteoporos Int 32:2173\u20132183. https:\/\/doi.org\/10.1007\/s00198-021-05963-x","journal-title":"Osteoporos Int"},{"key":"1603_CR48","doi-asserted-by":"publisher","first-page":"4443","DOI":"10.1007\/s00018-017-2585-y","volume":"74","author":"Z Luo","year":"2017","unstructured":"Luo Z, Liu Y, Liu Y et al (2017) Cellular and molecular mechanisms of alcohol-induced osteopenia. Cell Mol Life Sci 74:4443\u20134453. https:\/\/doi.org\/10.1007\/s00018-017-2585-y","journal-title":"Cell Mol Life Sci"},{"key":"1603_CR49","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1146\/annurev-physiol-060821-014008","volume":"84","author":"L Simon","year":"2022","unstructured":"Simon L, Souza-Smith FM, Molina PE (2022) Alcohol-associated tissue injury: current views on pathophysiological mechanisms. Annu Rev Physiol 84:87\u2013112. https:\/\/doi.org\/10.1146\/annurev-physiol-060821-014008","journal-title":"Annu Rev Physiol"},{"key":"1603_CR50","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1111\/apt.15087","volume":"49","author":"A Mantovani","year":"2019","unstructured":"Mantovani A, Dauriz M, Gatti D et al (2019) Systematic review with meta-analysis: non-alcoholic fatty liver disease is associated with a history of osteoporotic fractures but not with low bone mineral density. Aliment Pharmacol Ther 49:375\u2013388. https:\/\/doi.org\/10.1111\/apt.15087","journal-title":"Aliment Pharmacol Ther"},{"key":"1603_CR51","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1002\/jbmr.4862","volume":"38","author":"Y Su","year":"2023","unstructured":"Su Y, Chien K, Yang S et al (2023) Nonalcoholic fatty liver disease is associated with decreased bone mineral density in adults: a systematic review and meta-analysis. J Bone Miner Res 38:1092\u20131103. https:\/\/doi.org\/10.1002\/jbmr.4862","journal-title":"J Bone Miner Res"},{"key":"1603_CR52","doi-asserted-by":"publisher","DOI":"10.3390\/nu14214556","volume":"14","author":"K Riazi","year":"2022","unstructured":"Riazi K, Swain MG, Congly SE et al (2022) Race and ethnicity in non-alcoholic fatty liver disease (NAFLD): a narrative review. Nutrients 14:4556. https:\/\/doi.org\/10.3390\/nu14214556","journal-title":"Nutrients"},{"key":"1603_CR53","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2025.1717852","volume":"16","author":"X Li","year":"2025","unstructured":"Li X, Luo W, Chen K, Peng Y (2025) Association of metabolic dysfunction-associated steatotic liver disease with bone health in adults: a systematic review and meta-analysis of observational studies. Front Endocrinol (Lausanne) 16:1717852. https:\/\/doi.org\/10.3389\/fendo.2025.1717852","journal-title":"Front Endocrinol (Lausanne)"},{"key":"1603_CR54","doi-asserted-by":"publisher","DOI":"10.1007\/s11657-025-01627-z","volume":"21","author":"J Lee","year":"2025","unstructured":"Lee J, Yang Y-J (2025) Nonalcoholic fatty liver disease may increase the risk of osteoporosis in middle aged adults: a 12-year longitudinal analysis from the Korean Genome and Epidemiology Study (KoGES). Arch Osteoporos 21:3. https:\/\/doi.org\/10.1007\/s11657-025-01627-z","journal-title":"Arch Osteoporos"},{"key":"1603_CR55","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1156996","volume":"14","author":"GE Chung","year":"2023","unstructured":"Chung GE, Cho EJ, Kim MJ et al (2023) Association between the fatty liver index and the risk of fracture among individuals over the age of 50 years: a nationwide population-based study. Front Endocrinol (Lausanne) 14:1156996. https:\/\/doi.org\/10.3389\/fendo.2023.1156996","journal-title":"Front Endocrinol (Lausanne)"},{"key":"1603_CR56","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1111\/joim.13497","volume":"292","author":"A Wester","year":"2022","unstructured":"Wester A, Hagstr\u00f6m H (2022) Risk of fractures and subsequent mortality in non-alcoholic fatty liver disease: a nationwide population-based cohort study. J Intern Med 292:492\u2013500. https:\/\/doi.org\/10.1111\/joim.13497","journal-title":"J Intern Med"},{"key":"1603_CR57","doi-asserted-by":"publisher","DOI":"10.1002\/jbm4.10714","volume":"7","author":"SG Hansen","year":"2023","unstructured":"Hansen SG, Wernberg CW, Gr\u00f8nkj\u00e6r LL et al (2023) Are nonalcoholic fatty liver disease and bone mineral density associated? - a cross-sectional study using liver biopsy and dual-energy X-ray absorptiometry. JBMR Plus 7:e10714. https:\/\/doi.org\/10.1002\/jbm4.10714","journal-title":"JBMR Plus"},{"key":"1603_CR58","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0292881","volume":"18","author":"Q Huang","year":"2023","unstructured":"Huang Q, Guo J, Zhao H et al (2023) The associations of alcoholic liver disease and nonalcoholic fatty liver disease with bone mineral density and the mediation of serum 25-Hydroxyvitamin D: a bidirectional and two-step Mendelian randomization. PLoS ONE 18:e0292881. https:\/\/doi.org\/10.1371\/journal.pone.0292881","journal-title":"PLoS ONE"},{"key":"1603_CR59","doi-asserted-by":"publisher","first-page":"4038","DOI":"10.3748\/wjg.v21.i13.4038","volume":"21","author":"CS Bang","year":"2015","unstructured":"Bang CS, Shin IS, Lee SW et al (2015) Osteoporosis and bone fractures in alcoholic liver disease: a meta-analysis. World J Gastroenterol 21:4038\u20134047. https:\/\/doi.org\/10.3748\/wjg.v21.i13.4038","journal-title":"World J Gastroenterol"},{"key":"1603_CR60","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1038\/ajg.2010.413","volume":"106","author":"E Rom\u00e1n","year":"2011","unstructured":"Rom\u00e1n E, C\u00f3rdoba J, Torrens M et al (2011) Minimal hepatic encephalopathy is associated with falls. Am J Gastroenterol 106:476\u2013482. https:\/\/doi.org\/10.1038\/ajg.2010.413","journal-title":"Am J Gastroenterol"},{"key":"1603_CR61","doi-asserted-by":"publisher","first-page":"1922","DOI":"10.1002\/hep.25554","volume":"55","author":"G Soriano","year":"2012","unstructured":"Soriano G, Rom\u00e1n E, C\u00f3rdoba J et al (2012) Cognitive dysfunction in cirrhosis is associated with falls: a prospective study. Hepatology 55:1922\u20131930. https:\/\/doi.org\/10.1002\/hep.25554","journal-title":"Hepatology"},{"key":"1603_CR62","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics14050510","volume":"14","author":"M Stulic","year":"2024","unstructured":"Stulic M, Jadzic J, Dostanic N et al (2024) Clinical indicators of bone deterioration in alcoholic liver cirrhosis and chronic alcohol abuse: looking beyond bone fracture occurrence. Diagnostics (Basel) 14:510. https:\/\/doi.org\/10.3390\/diagnostics14050510","journal-title":"Diagnostics (Basel)"},{"key":"1603_CR63","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1016\/j.jhep.2018.04.002","volume":"69","author":"H Otete","year":"2018","unstructured":"Otete H, Deleuran T, Fleming KM et al (2018) Hip fracture risk in patients with alcoholic cirrhosis: a population-based study using English and Danish data. J Hepatol 69:697\u2013704. https:\/\/doi.org\/10.1016\/j.jhep.2018.04.002","journal-title":"J Hepatol"},{"key":"1603_CR64","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1016\/j.cgh.2022.05.048","volume":"21","author":"A Wester","year":"2023","unstructured":"Wester A, Ndegwa N, Hagstr\u00f6m H (2023) Risk of fractures and subsequent mortality in alcohol-related cirrhosis: a nationwide population-based cohort study. Clin Gastroenterol Hepatol 21:1271-1280.e7. https:\/\/doi.org\/10.1016\/j.cgh.2022.05.048","journal-title":"Clin Gastroenterol Hepatol"},{"key":"1603_CR65","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.clnesp.2025.07.002","volume":"69","author":"S Yokoyama","year":"2025","unstructured":"Yokoyama S, Honda T, Ishizu Y et al (2025) Impact of alcohol consumption and muscle mass on bone mineral density in metabolic dysfunction and alcohol-associated liver disease (MetALD) and metabolic dysfunction-associated steatotic liver disease (MASLD). Clin Nutr ESPEN 69:145\u2013153. https:\/\/doi.org\/10.1016\/j.clnesp.2025.07.002","journal-title":"Clin Nutr ESPEN"},{"key":"1603_CR66","doi-asserted-by":"publisher","DOI":"10.1155\/cjgh\/6969761","author":"T Wu","year":"2025","unstructured":"Wu T, Li L, Mei Y et al (2025) Increased BMD in SLD patients without advanced hepatic fibrosis: evidence from the NHANES 2017-2020 database. Can J Gastroenterol Hepatol. https:\/\/doi.org\/10.1155\/cjgh\/6969761","journal-title":"Can J Gastroenterol Hepatol"},{"key":"1603_CR67","doi-asserted-by":"publisher","first-page":"302","DOI":"10.3389\/fendo.2019.00302","volume":"10","author":"E Dalla Grana","year":"2019","unstructured":"Dalla Grana E, Rigo F, Lanzafame M et al (2019) Relationship between vertebral fractures, bone mineral density, and osteometabolic profile in HIV and hepatitis B and C-infected patients treated with ART. Front Endocrinol 10:302. https:\/\/doi.org\/10.3389\/fendo.2019.00302","journal-title":"Front Endocrinol"},{"key":"1603_CR68","doi-asserted-by":"publisher","first-page":"1688","DOI":"10.1002\/hep.25866","volume":"56","author":"V Lo Re","year":"2012","unstructured":"Lo Re V, Volk J, Newcomb CW et al (2012) Risk of hip fracture associated with hepatitis C virus infection and hepatitis C\/human immunodeficiency virus coinfection. Hepatology 56:1688\u20131698. https:\/\/doi.org\/10.1002\/hep.25866","journal-title":"Hepatology"},{"key":"1603_CR69","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13206152","volume":"13","author":"SH Loosen","year":"2024","unstructured":"Loosen SH, Killer A, Bock HH et al (2024) Association between chronic hepatitis B\/C and incidence of osteoporosis and bone fractures: results from a retrospective cohort study. J Clin Med 13:6152. https:\/\/doi.org\/10.3390\/jcm13206152","journal-title":"J Clin Med"},{"key":"1603_CR70","doi-asserted-by":"publisher","DOI":"10.20452\/pamw.16942","author":"J Janczura","year":"2025","unstructured":"Janczura J, Brzd\u0119k M, Dobrowolska K et al (2025) Steatotic liver disease in patients treated for chronic hepatitis B. Pol Arch Intern Med. https:\/\/doi.org\/10.20452\/pamw.16942","journal-title":"Pol Arch Intern Med"},{"key":"1603_CR71","doi-asserted-by":"publisher","first-page":"1120083","DOI":"10.3389\/fmed.2023.1120083","volume":"10","author":"J Tao","year":"2023","unstructured":"Tao J, Yan Z, Huang W, Feng T (2023) Seropositive for hepatitis B and C viruses is associated with the risk of decreased bone mineral density in adults: An analysis of studies from the NHANES database. Front Med (Lausanne) 10:1120083. https:\/\/doi.org\/10.3389\/fmed.2023.1120083","journal-title":"Front Med (Lausanne)"},{"key":"1603_CR72","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1111\/liv.13730","volume":"38","author":"N Gua\u00f1abens","year":"2018","unstructured":"Gua\u00f1abens N, Par\u00e9s A (2018) Osteoporosis in chronic liver disease. Liver Int 38:776\u2013785. https:\/\/doi.org\/10.1111\/liv.13730","journal-title":"Liver Int"},{"key":"1603_CR73","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.25106","author":"M Zoulakis","year":"2024","unstructured":"Zoulakis M, Sundh D, Lorentzon M (2024) Type 2 diabetes and fracture risk in older women: findings from the SUPERB cohort. JAMA Netw Open. https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.25106","journal-title":"JAMA Netw Open"},{"key":"1603_CR74","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/j.clnu.2016.12.030","volume":"37","author":"JF Garc\u00eda-Gavil\u00e1n","year":"2018","unstructured":"Garc\u00eda-Gavil\u00e1n JF, Bull\u00f3 M, Canudas S et al (2018) Extra virgin olive oil consumption reduces the risk of osteoporotic fractures in the PREDIMED trial. Clin Nutr 37:329\u2013335. https:\/\/doi.org\/10.1016\/j.clnu.2016.12.030","journal-title":"Clin Nutr"},{"key":"1603_CR75","doi-asserted-by":"publisher","first-page":"2085","DOI":"10.1136\/gutjnl-2020-323106","volume":"70","author":"A Yaskolka Meir","year":"2021","unstructured":"Yaskolka Meir A, Rinott E, Tsaban G et al (2021) Effect of green-Mediterranean diet on intrahepatic fat: the DIRECT PLUS randomised controlled trial. Gut 70:2085\u20132095. https:\/\/doi.org\/10.1136\/gutjnl-2020-323106","journal-title":"Gut"},{"key":"1603_CR76","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1093\/ajcn\/nqy122","volume":"108","author":"A Jennings","year":"2018","unstructured":"Jennings A, Cashman KD, Gillings R et al (2018) A Mediterranean-like dietary pattern with vitamin D3 (10 \u03bcg\/d) supplements reduced the rate of bone loss in older Europeans with osteoporosis at baseline: results of a 1-y randomized controlled trial. Am J Clin Nutr 108:633\u2013640. https:\/\/doi.org\/10.1093\/ajcn\/nqy122","journal-title":"Am J Clin Nutr"},{"key":"1603_CR77","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2023.1105303","volume":"14","author":"Z Wang","year":"2023","unstructured":"Wang Z, Zan X, Li Y et al (2023) Comparative efficacy different resistance training protocols on bone mineral density in postmenopausal women: a systematic review and network meta-analysis. Front Physiol 14:1105303. https:\/\/doi.org\/10.3389\/fphys.2023.1105303","journal-title":"Front Physiol"},{"key":"1603_CR78","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.jhep.2018.06.024","volume":"70","author":"European Association for the Study of the Liver","year":"2019","unstructured":"European Association for the Study of the Liver (2019) EASL clinical practice guidelines on nutrition in chronic liver disease. J Hepatol 70:172\u2013193. https:\/\/doi.org\/10.1016\/j.jhep.2018.06.024","journal-title":"J Hepatol"},{"key":"1603_CR79","doi-asserted-by":"publisher","first-page":"1702","DOI":"10.1111\/dom.14774","volume":"24","author":"ID Vachliotis","year":"2022","unstructured":"Vachliotis ID, Anastasilakis AD, Goulas A et al (2022) Nonalcoholic fatty liver disease and osteoporosis: a potential association with therapeutic implications. Diabetes Obes Metab 24:1702\u20131720. https:\/\/doi.org\/10.1111\/dom.14774","journal-title":"Diabetes Obes Metab"},{"key":"1603_CR80","doi-asserted-by":"publisher","first-page":"4960","DOI":"10.3748\/wjg.v26.i33.4960","volume":"26","author":"C Saeki","year":"2020","unstructured":"Saeki C, Saito M, Oikawa T et al (2020) Effects of denosumab treatment in chronic liver disease patients with osteoporosis. World J Gastroenterol 26:4960\u20134971. https:\/\/doi.org\/10.3748\/wjg.v26.i33.4960","journal-title":"World J Gastroenterol"},{"key":"1603_CR81","doi-asserted-by":"publisher","DOI":"10.1177\/10600280251322002","author":"K Nowak","year":"2025","unstructured":"Nowak K, \u0141upina K, Romac A et al (2025) Therapeutic potential of GLP-1 receptor agonists in metabolic associated steatotic liver disease. Ann Pharmacother. https:\/\/doi.org\/10.1177\/10600280251322002","journal-title":"Ann Pharmacother"},{"key":"1603_CR82","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1007\/s00592-025-02468-5","volume":"62","author":"Y Tan","year":"2025","unstructured":"Tan Y, Liu S, Tang Q (2025) Effect of GLP-1 receptor agonists on bone mineral density, bone metabolism markers, and fracture risk in type 2 diabetes: a systematic review and meta-analysis. Acta Diabetol 62:589\u2013606. https:\/\/doi.org\/10.1007\/s00592-025-02468-5","journal-title":"Acta Diabetol"}],"container-title":["Calcified Tissue International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00223-026-01603-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00223-026-01603-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00223-026-01603-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T08:58:31Z","timestamp":1789549111000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00223-026-01603-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,16]]},"references-count":82,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1603"],"URL":"https:\/\/doi.org\/10.1007\/s00223-026-01603-w","relation":{},"ISSN":["1432-0827"],"issn-type":[{"value":"1432-0827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,16]]},"assertion":[{"value":"6 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent to Participate","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"143"}}